Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

929 questions · 946 findings · 295 reviews · Headline outcomes only

No studies found 150 · 15.9%GRADE not reported 47 · 5%Very low 312 · 33%Low 262 · 27.7%Moderate 138 · 14.6%High 37 · 3.9%

Omega‐3 vs placebo

Change in visual loss associated with PSR: visual loss is defined by the deterioration of visual acuity of 3 lines or more with the Snellen chart · people with AMD

Omega 3 fatty acids probably leads to higher loss of 3 or more lines of VA at 24 months compared with placebo (moderate certainty).

2 findings from 1 review

Indacaterol vs placebo

Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease

Indacaterol leads to lower number of participants experiencing 1 or more exacerbations compared with placebo (high certainty).

1 finding from 1 review

Ruxolitinib vs placebo

Health‐related quality of life Patients that achieved a reduction of 50% or more in the total MF Symptom Assessment Form · Patients with treating MF

Ruxolitinib may leads to higher health‐related quality of life Patients that achieved a reduction of… compared with placebo (low certainty).

1 finding from 1 review

FAE vs placebo

PASI score (scale range from 0 to 72 (higher score indicates more severe psoriasis)) · psoriasis
1 finding from 1 review

FAE vs MTX

PASI score (scale range from 0 to 72 (higher score indicates more severe psoriasis)) · psoriasis
1 finding from 1 review

Intervention not reported

Change in long‐term disability more than 3 months after the intervention Measure:6MWT · People with multiple sclerosis
1 finding from 1 review

Intervention not reported

Change in long‐term impairments more than 3 months after the intervention Measures: FIS, FSS · People with multiple sclerosis
1 finding from 1 review

PFMT added to electrical stimulation vs electrical stimulation alone (excluding implanted electrodes)

Number of women reporting incontinence at 1 year or more after treatment (subjective) ‐ not reported · women with urinary incontinence

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Progression (increase in maximal keratometry of 1.5 dioptres or more) · people with keratoconus

It is very uncertain whether the intervention changes progression (increase in maximal keratometry of 1.5 dioptres or more) (very low certainty).

1 finding from 1 review

Rapid COJEC vs standard induction therapies

Early toxicities (during preoperative chemotherapy): febrile neutropenia (2 or more episodes), proven fungal infections, septicemia (1 or more episodes), gastrointestinal toxicity (grade 3 or 4), renal toxicity (glomerular filtration rate < 80 ml/... · patients with high‐risk neuroblastoma
1 finding from 1 review